# SAKAE CORPORATION

# 510(k) Summary

1 Applicant   
SAKAE CORPORATION   
239 Onishi, Fujioka, Gunma, 370-1401 JAPAN   
Phone: (81)-274-52-3126 Fax: (81)-274-52-4240

2 Contact Information: Erika B. Ammirati, R. A. C., MT (ASCP) Regulatory Consultant to SAKAE CORPORATION Phone: (650) 949-2768 E-mail: erikaba@pacbell.net

3 Device Trade Name: Alc GEAR System

4 Device Common Name: Glycs al

5 Manufacturer Address   
SAKAE CORPORATION   
239 Onishi, Fujioka, Gunma, 370-1401 JAPAN   
Phone: (81)-274-52-3126 Fax: (81)-274-52-4240

6 Device Classification:

SAKAE CORPORATION Alc GEAR System (new) is a Class II device and reagent, and is classified by FDA under 21 CFR 864.7470 Glycosylated hemoglobin assay and the FDA Product Code is LCP.

Alc GEAR (the instrument) is a Class I device and is classified by FDA under 21 CFR 862.2160, Discrete photometric chemistry analyzer for clinical use, and the FDA Product Code is JJE.

# 7 Device Description:

The A 1c GEAR instrument is a fully automated desktop electric spectrophotometer that measures %HbAlc in human whole blood using a dedicated reagent (MEDIDAS HbA1c). The system illuminates a $6 6 0 \ \mathsf { n m }$ LED (Light Emitting Diode) through the test material and quantitatively measures the percent of hemoglobin Alc in the total hemoglobin (%HbA1c) by means of light absorbance changes and a non-linear calibration curve. The system includes the Hemoglobin Alc Analyzer (Alc GEAR), thermal printer, barcode reader, power cable, and fan filter.

MEDIDAS HbA 1c is composed of a test cartridge, capillary, pipette tip and master calibration card. The cartridge is pre-flled with reagent; latex (reagent R1), antibody (reagent R2), and sample dilute solution.

# 8 Indications for Use

The Alc GEAR System is intended for in vitro diagnostic use only for the quantitative measurement of the percent hemoglobin A1c (%HbAlc) from finger-stick blood or venous whole blood collected in either EDTA or sodium fluoride (NaF) for clinical laboratory and point of care use. The measurement of HbAlc is recommended to monitor long-term glycemic control of persons previously diagnosed with diabetes mellitus. This test is not for screening or diagnosis of diabetes.

# 9 Limitations

$\bullet$ This test should not be used in monitoring daily glucose control.   
$\bullet$ Should not be used to replace daily home testing of urine and blood glucose levels.   
$\bullet$ Should not be used for analyzing samples from patients with conditions causing shortened red blood cell survival, such as hemolytic diseases, pregnancy and significant acute or chronic blood loss.

# 10 Expected Values and Reference (non-diabetic) Level

The American Diabetes Association (ADA) expected value range is $4 . 0 { - } 6 . 0 \%$ HbA lc for people without diabetes.

The American Diabetes Association's (ADA) most recent Clinical Practice recommendation for diabetes specified a treatment goal of less than $7 \%$ and suggests additional action when HbA1c is above $8 \%$ EMPY

<table><tr><td rowspan=1 colspan=1>HbA1c Value</td><td rowspan=1 colspan=1>Glycemic Goal</td></tr><tr><td rowspan=1 colspan=1>&lt;8% HbAIc</td><td rowspan=1 colspan=1>Less stringent</td></tr><tr><td rowspan=1 colspan=1>&lt;7% HbAIc</td><td rowspan=1 colspan=1>General (Non-Pregnant Adults)</td></tr><tr><td rowspan=1 colspan=1>&lt;6.5% HbA1c</td><td rowspan=1 colspan=1>More stringent</td></tr></table>

American Diabetes Association Standards of Medical Care in Diabetes 2012, 35   
(Supplement1), S11-S63

# 11 Predicate Device

DCA Vantage, a test system for hemoglobin Alc by Siemens Medical Solutions Diagnostics, K071466. The predicate device has the same intended use, uses substantially the same assay methodology, and is substantially equivalent to the Alc GEAR System.

Device Comparison Chart   

<table><tr><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>SAKAE CORPORATION</td><td rowspan=1 colspan=1>Siemens Medical Solutions Diagnostics</td></tr><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=1>Alc GEAR System</td><td rowspan=1 colspan=1>DCA Vantage</td></tr><tr><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>K130014</td><td rowspan=1 colspan=1>K071466</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>LCP</td><td rowspan=1 colspan=1>LCP</td></tr><tr><td rowspan=1 colspan=1>Regulation Number</td><td rowspan=1 colspan=1>864.7470</td><td rowspan=1 colspan=1>864.7470</td></tr><tr><td rowspan=1 colspan=1>Indications for use:</td><td rowspan=1 colspan=1>Quantitative measurement of percenthemoglobin Alc in human wholeblood</td><td rowspan=1 colspan=1>Quantitative measurement of percenthemoglobin Alc in human whole blood</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Immuno-turbidimetric</td><td rowspan=1 colspan=1>Immuno-turbidimetric (inhibition)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Finger-stick blood or venous wholeblood collected in K2 EDTA orsodium fluoride</td><td rowspan=1 colspan=1>Finger-stick blood or venous whole bloodcollected in EDTA, heparin,fluoride/oxalate, and citrate</td></tr><tr><td rowspan=1 colspan=1>Visual Display</td><td rowspan=1 colspan=1>LCD</td><td rowspan=1 colspan=1>LCD</td></tr><tr><td rowspan=1 colspan=1>Hemolysate preparation</td><td rowspan=1 colspan=1>Automatic</td><td rowspan=1 colspan=1>Automatic</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Transmission</td><td rowspan=1 colspan=1>Transmission</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>User; calibration card</td><td rowspan=1 colspan=1>User; calibration card</td></tr><tr><td rowspan=1 colspan=1>Recommended testingenvironment</td><td rowspan=1 colspan=1>Professional use; point of care</td><td rowspan=1 colspan=1>Professional use; point of care</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=1>6-7 minutes per sample</td><td rowspan=1 colspan=1>6-7 minutes per sample</td></tr><tr><td rowspan=1 colspan=1>Analytical Range</td><td rowspan=1 colspan=1>4.3-12.5%</td><td rowspan=1 colspan=1>2.5-14.0%</td></tr><tr><td rowspan=1 colspan=1>Reagent Storage</td><td rowspan=1 colspan=1>2-8 degrees Celsius (36-46 degreesFahrenheit</td><td rowspan=1 colspan=1>2-8 degrees Celsius (36-46 degreesFahrenheit)</td></tr><tr><td rowspan=1 colspan=1>Accuracy (Comparison)</td><td rowspan=1 colspan=1>Versus HPLC methodY=1.03x-0.33, R=0.99 N=158</td><td rowspan=1 colspan=1>Versus DCCT reference method (HPLC)Y=1.02x-0.00, R=0.98 N=100</td></tr><tr><td rowspan=1 colspan=1>NGSP Certification Status</td><td rowspan=1 colspan=1>Certified</td><td rowspan=1 colspan=1>Certified</td></tr><tr><td rowspan=1 colspan=1>Complies with [EC 60601-1</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Complies with IEC 60601-1-2</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr></table>

# 12 Performance Data

# 12.1 Linearity

Linearity of the Alc GEAR System was verified with the use of two whole blood samples collected into EDTA tubes. Sample low $( \mathrm { L } ; 4 . 0 \%$ HbA 1c, result from ion-exchange HPLC) and high $X 1 : 1 5 . 0 \%$ HbA1c, result from ion-exchange HPLC) were mixed in different proportions to obtain a series of 1 1 samples. Allsamples were measured in triplicate. Recovery rate was used as an indicator for the degree of the deviation of expected values. The linear regression analysis was performed.

239 Onishi, Fujioka-shi, Gunma, 370-1401 Japan Phone: +81-274-52-3126, Fax: $+ 8 1$ -274-52-4240

Table 1 Linearity of the AIc GEAR System. Y: observed value, X: expected value, $\mathbf { r } ^ { 2 }$ : squared coefficient of correlation, recovery $( \% ) =$ observed value / expected value $\mathbf { x }$ 100.   

<table><tr><td rowspan=1 colspan=1>Range (% HbAlc)</td><td rowspan=1 colspan=1>•    Regression line</td><td rowspan=1 colspan=1>r^2}$</td><td rowspan=1 colspan=1> Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>4.0 - 13.1</td><td rowspan=1 colspan=1>y=0.98x + 0.19</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>98 - 103</td></tr></table>

# 12.2 Method Comparisons (venous to venous sampling, in-house)

Method comparison studies were performed with three comparison methods; two different ion-exchange HPLC methods and one point of care (POC, DCA Vantage) method were each compared to the Alc GEAR System. Venous whole blood collected into EDTA tubes were prepared from donors and analyzed.

Table 2 Linear regression analysis data of method comparison. Y: A1c GEAR, X: comparison method, N: number of samples, $\mathbf { r } ^ { 2 } ;$ squared coefficient of correlation.   

<table><tr><td rowspan=1 colspan=1>Comparison Method</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>HbA1c (%)</td><td rowspan=1 colspan=1>Regression Line</td><td rowspan=1 colspan=1>$r^2 }$</td></tr><tr><td rowspan=1 colspan=1>HPLC 1</td><td rowspan=1 colspan=1>158•</td><td rowspan=1 colspan=1>4.6-10.6</td><td rowspan=1 colspan=1>y = 1.03x - 0.33</td><td rowspan=1 colspan=1>0.98</td></tr><tr><td rowspan=1 colspan=1>HPLC 2</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>4.2-9.8</td><td rowspan=1 colspan=1>y = 0.99x + 0.31</td><td rowspan=1 colspan=1>0.98</td></tr><tr><td rowspan=1 colspan=1>Another POC analyzer (DCAVantage)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>4.7-11.7</td><td rowspan=1 colspan=1>y = 0.95x - 0.12</td><td rowspan=1 colspan=1>0.99</td></tr></table>

# 12.3 Matrix Comparison

Matrix comparison studies were performed to evaluate the effect of the sample matrix. A finger-stick sample and venous whole blood samples with anticoagulants EDTA or sodium fluoride (NaF), were collected from each donor and analyzed with the Alc GEAR System.

Table 3 Linear regression analysis data of matrix comparison. N: number of samples, $\mathbf { r } ^ { 2 }$ : squared coefficient of correlation.   

<table><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>HbA1c (%)</td><td rowspan=1 colspan=1>Regression line</td><td rowspan=1 colspan=1>$r^2}$</td></tr><tr><td rowspan=1 colspan=1>finger (y) vs. EDTA-venous (x)</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>4.3-9.0</td><td rowspan=1 colspan=1>y= 0.96x +0.15</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>NaF-venous (y) vs. finger (x)</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>4.8-8.8</td><td rowspan=1 colspan=1>y=1.04x - 0.06</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>NaF-venous (y) vs. EDTA-venous (x)</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>5.3-10.9</td><td rowspan=1 colspan=1>y=1.01x+0.01</td><td rowspan=1 colspan=1>0.99</td></tr></table>

# 12.4 Precision

Precision studies were performed at both internal and external sites. The studies followed CLSI (Clinical and Laboratory Standards Institute) Guideline EP5-A2.

Within-run (repeatability), between-day, and total precision were determined for two control materials (control L and H) and three EDTA whole blood samples at the internal site, and with two control materials (control L and H) and two EDTA whole blood samples at the external site. The samples were analyzed for 20 days, in duplicate, twice a day $( \boldsymbol { \mathrm { n } } = 8 0 )$

Table 4 Results from the internal site. %CV: %coefficient of variation.   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-run CV (%)</td><td rowspan=1 colspan=1>Between-day CV (%)</td><td rowspan=1 colspan=1>Total CV (%)</td></tr><tr><td rowspan=1 colspan=1>Control L</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>1.36</td></tr><tr><td rowspan=1 colspan=1>Control H</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>1.06</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>1.12</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.37</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>1.52</td></tr></table>

Table 5 Results from the external site. $\% \mathbf { C V }$ $\%$ coefficient of variation.   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-run CV (%)</td><td rowspan=1 colspan=1>Between-day CV (%)</td><td rowspan=1 colspan=1>Total CV (%)</td></tr><tr><td rowspan=1 colspan=1>Control L</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.31</td></tr><tr><td rowspan=1 colspan=1>Control H</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>0.90</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>1.34</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.82</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.05</td></tr></table>

Table 6 Reproducibility estimated from the results of two sites. $\% \mathbf { C V }$ %coefficient of variation.   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Overall mean</td><td rowspan=1 colspan=1>Between-site CV (%)</td><td rowspan=1 colspan=1>Total CV (%)</td></tr><tr><td rowspan=1 colspan=1>Control L</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>2.81</td></tr><tr><td rowspan=1 colspan=1>Control H</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.94</td></tr></table>

# 12.5 Point of Care (POC) Studies

External validation of the Alc GEAR System was performed at POC sites to evaluate precision and method comparisons.

In pen sudy, hre lve ntrs we nalyze  0 days and thre evel pn samples were analyzed for 10 days by POC operators.

# SAKAE CORPORATION

239 Onishi, Fujioka-shi, Gunma, 370-1401 Japan Phone: +81-274-52-3126, Fax: +81-274-52-4240

Table 7 Results of precision study at three external sites. %CV: $\%$ coefficient of variation.   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N =</td><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-siteCV (%)</td><td rowspan=1 colspan=1>Overall mean</td><td rowspan=1 colspan=1>ReproducibilityTotal CV (%)</td></tr><tr><td rowspan=3 colspan=1>Control 1</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.19</td><td rowspan=1 colspan=1>2.85%</td><td rowspan=3 colspan=1>5.22</td><td rowspan=3 colspan=1>2.26%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.21</td><td rowspan=1 colspan=1>1.92%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.27</td><td rowspan=1 colspan=1>1.46%</td></tr><tr><td rowspan=3 colspan=1>Control 2</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.01</td><td rowspan=1 colspan=1>2.53%</td><td rowspan=3 colspan=1>7.06</td><td rowspan=3 colspan=1>2.11%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.07</td><td rowspan=1 colspan=1>1.73%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7.10</td><td rowspan=1 colspan=1>1.73%</td></tr><tr><td rowspan=3 colspan=1>Control 3</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11.05</td><td rowspan=1 colspan=1>3.37%</td><td rowspan=3 colspan=1>11.04</td><td rowspan=3 colspan=1>2.55%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11.09</td><td rowspan=1 colspan=1>2.48%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11.00</td><td rowspan=1 colspan=1>1.35%</td></tr><tr><td rowspan=3 colspan=1>Sample Low</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.80</td><td rowspan=1 colspan=1>3.14%</td><td rowspan=3 colspan=1>5.84</td><td rowspan=3 colspan=1>3.12%</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.83</td><td rowspan=1 colspan=1>3.28%</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.89</td><td rowspan=1 colspan=1>2.63%</td></tr><tr><td rowspan=3 colspan=1>Sample Middle</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.01</td><td rowspan=1 colspan=1>3.31%</td><td rowspan=3 colspan=1>8.07</td><td rowspan=3 colspan=1>4.16%</td></tr><tr><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.87</td><td rowspan=1 colspan=1>2.30%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8.34</td><td rowspan=1 colspan=1>2.91%</td></tr><tr><td rowspan=3 colspan=1>Sample High</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.55</td><td rowspan=1 colspan=1>3.22%</td><td rowspan=3 colspan=1>10.84</td><td rowspan=3 colspan=1>5.25%</td></tr><tr><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>10.59</td><td rowspan=1 colspan=1>2.46%</td></tr><tr><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11.38</td><td rowspan=1 colspan=1>3.21%</td></tr></table>

In the method comparison study, a finger-stick sample and a venous EDTA sample were collected from each donor. The finger-stick blood samples were analyzed with the A1c GEAR System by POC operators and the venous blood samples were analyzed with an ion-exchange HPLC (Tosoh, G8) reference method by qualified laboratory technicians at a reference laboratory.

Table 8 Linear regression analysis of method comparison study at three external sites. N: number of samples, r: coefficient of correlation.   

<table><tr><td rowspan=1 colspan=1>Studysite</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>Slope(95% confidence interval)</td><td rowspan=1 colspan=1>Intercept(95% confidence interval)</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>0.968(0.941 to 0.994)</td><td rowspan=1 colspan=1>0.04(-0.16 to 0.24)</td><td rowspan=1 colspan=1>0.995</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>0.976(0.936 to 1.015)</td><td rowspan=1 colspan=1>0.12(-0.15 to 0.40)</td><td rowspan=1 colspan=1>0.990</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>0.989(0.952 to 1.027)</td><td rowspan=1 colspan=1>0.08(-0.18 to 0.35)</td><td rowspan=1 colspan=1>0.990</td></tr></table>

# 12.6 Interference

No significant interference was observed up to the following concentrations in both EDTA and NaF whole blood samples, or commercial controls:

Free - bilirubin 37.0 mg/dl Conjugated - bilirubin 40.4 mg/dl Rheumatoid factor $5 5 0 ~ \mathrm { I U / m l }$ EPY Chyle (mixture of lipids) 3120 FTU (Formazine Turbidity Unit) includes: Triglycerides 170 mg/dl Phospholipids 182 mg/dl Free fatty acids 124 μEq/dl (approx. 1.24 mmol/l) Triglycerides (separate study) 2,000 mg/dl Acetaminophen 20.0 mg/dl • Ibuprofen 50.0 mg/dl • Glibenclamide 0.2 mg/dl Metformin 5.1 mg/dl • Ascorbic acid 6.0 mg/dl

NOTE: It is possible that other substances and/or factors not listed above may interfere with the test and cause false results.

# 12.7 Analytical Specificity

# 12.7.1 Hemoglobin (Hb) Variants

A hemoglobin variant study was performed using commercial samples known to contain Hemoglobin variants C, D, E, S and F. Samples contained both low and high levels of %HbA 1c at concentrations from $4 . 6 \mathrm { - } 1 1 . 6 \%$ . These variant samples were tested in duplicate using the Alc GEAR System versus a reference method (Primus Ultra Boronate Affinity HPLC). The results indicated samples containing Hemoglobin C were elevated by $2 4 \%$ , samples containing Hemoglobin D were elevated by $1 6 \%$ , samples containing Hemoglobin E were elevated by $1 3 \%$ EPY and samples containing Hemoglobin S were elevated by $14 \%$ Samples containing $> 1 0 \%$ Hemoglobin F were decreased by $3 2 \%$ . All variants tested were shown to interfere with this device.

# 12.7.2 Modified Hemoglobin

The following modified hemoglobin was prepared by incubating with the substance in parentheses and found not to affect the A1c GEAR System for both EDTA and NaF whole blood samples:

• Carbamylated hemoglobin (sodium cyanate, $1 0 \mathrm { m g / d l }$ L Acetylated hemoglobin (acetylsalicylic acid, $2 0 0 { \mathrm { m g / d l } } ,$ Labile hemoglobin (D-glucose, $2 0 0 0 \mathrm { m g / d l } _ { , }$

# 12.8 Limit of Detection

Te  a alHAcr GEA  m (LOD) studies were performed and LOD was calculated to be $2 . 6 \%$ and LOB was calculated to be $2 . 3 \%$ .

# 12.9 Stability- Real-Time

A real time shelf ife stability study was performed for MEDIDAS HbA1c using the Alc GEAR alyzer. Fro theeresuls it ws cncue that  reage crtriecan be store orup year at $2 { \cdot } 8 ~ ^ { \circ } \mathrm { C }$ EPY $( 3 6 { \cdot } 4 6 ^ { \circ } \mathrm { F } )$

# 13 Conclusions

Performance studies were conducted and the data obtained indicate the Alc GEAR System is substantially equivalent to the predicate device.

April 4, 2014

# SAKAE CORPORATION C/O ERICA AMMIRATI 575 SHIRLYNN COURT LOS ALTOS CA 94022

Re: K130014 Trade/Device Name: Alc Gear System Regulation Number: 21 CFR 864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: II Product Code: LCP, JJE Dated: March 28, 2014 Received: March 31, 2014

Dear Ms. Ammirati:

We have reviewed your Section $\mathfrak { s l o } ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to viha  esn   in  lD and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title1, Parts 800 to 88.In addition, FDAmay publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act Or any Federal statutes and regulations administered by other Federal agencies. You must. comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2-Ms. Ammirati

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 8, please contact the Division of Small Manufacturers. International and Consumer Assistance at its to1l-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.htum. Also. please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 80.9 For questions regarding the reporting of adverse events under the MDR regulation 21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Survcillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.htm.

Sincerely yours.

# Courtney H. Lias -S

Enclosure

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known) K130014

Indications for Use (Describe)   
TA y diagnosed with diabetes mellitus. This test is not or screening or diagnosis o diabes.

FORM FDA 3881 (1/14)